ProQR Therapeutics N.V appointed Dr. Art Levin, Dr. Phil Zamore, Dr. Cy Stein, Dr. Scott Armstrong, and Dr. Annemieke Aartsma-Rus as Advisory Board. Art Levin PhD, has more than two decades of experience in RNA drug development from discovery through drug registration, both in large pharma and biotech companies. He has been key to the development of numerous of oligonucleotides, including the first approved antisense medicines, and the first microRNA-targeted therapeutic in clinical trials. He is currently the Executive Vice President, Research and Development at Avidity Biosciences, Dr. Levin has published over 60 scientific articles and served as a director of the Oligonucleotide Therapeutics Society. Phil Zamore PhD is a Howard Hughes Medical Institute Investigator, Gretchen Stone Cook Chair of Biomedical Sciences, Professor of Biochemistry and Molecular Pharmacology, and Chair of the RNA Therapeutics Institute at the University of Massachusetts Medical School. He is also a co-founder of Alnylam Pharmaceuticals and Voyager Therapeutics. Dr. Zamore and his coworkers have played a role in nearly all of the major breakthroughs in the study of RNA silencing. Cy Stein PhD, MD, is a Professor of Medical Oncology and Molecular and Cellular Biology and the former chair of the Department of Medical Oncology & Therapeutics Research at City of Hope, overseeing the department’s clinical and research programs. He was co-editor-in-chief of Nucleic Acid Therapeutics for over 20 years and the series editor for Perspectives in Antisense Science. Dr. Stein has been named a top physician in his field by New York Times Magazine and New York Magazine, he has been awarded 11 patents, and he has published widely in prominent journals, including Science, Nature Biotechnology and Annals of Internal Medicine. Scott Armstrong MD, PhD, is an internationally renowned pediatric clinician and scientist. He is the Chair of the Department of Pediatric Oncology at Dana-Farber Cancer Institute, and the David G. Nathan Professor of Pediatrics at Dana-Farber Cancer Institute, Boston Children’s Hospital and Harvard Medical School. He is also Associate Chief of the Division of Hematology and Oncology at Boston Children’s Hospital. Dr. Armstrong previously held a variety of roles at Memorial Sloan Kettering Cancer Center in New York, NY, including in the Cancer Biology and Genetics Program and the Department of Pediatrics. Annemieke Aartsma-Rus PhD, professor of Translational Genetics at the Leiden University Medical Center, has played an important role in the development of the antisense mediated exon skipping therapy for Duchenne muscular dystrophy (DMD). In 2015 and 2016 she was selected as the most influential scientist in DMD in the past 10 years by Expertscape. Dr. Aartsma-Rus has coordinated stakeholder meetings involving academics, industry, regulators and patient representatives, including two hosted by the European Medicine Agencies in April 2015 and November 2016.